menu
    • menu
    [{"orgOrder":0,"company":"Universidad Peruana Cayetano Heredia","sponsor":"Oxfendazole Development Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PERU","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fenbendazole","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Universidad Peruana Cayetano Heredia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad Peruana Cayetano Heredia \/ Oxfendazole Development Group","highestDevelopmentStatusID":"9","companyTruncated":"Universidad Peruana Cayetano Heredia \/ Oxfendazole Development Group"},{"orgOrder":0,"company":"Universidad Peruana Cayetano Heredia","sponsor":"National Institute of Allergy and Infectious Diseases | Oxfendazole Development Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PERU","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fenbendazole","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Universidad Peruana Cayetano Heredia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad Peruana Cayetano Heredia \/ National Institute of Allergy and Infectious Diseases | Oxfendazole Development Group","highestDevelopmentStatusID":"8","companyTruncated":"Universidad Peruana Cayetano Heredia \/ National Institute of Allergy and Infectious Diseases | Oxfendazole Development Group"},{"orgOrder":0,"company":"Oxfendazole Development Group","sponsor":"Universidad Peruana Cayetano Heredia, Lima, Peru","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fenbendazole","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oxfendazole Development Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oxfendazole Development Group \/ Universidad Peruana Cayetano Heredia, Lima, Peru","highestDevelopmentStatusID":"8","companyTruncated":"Oxfendazole Development Group \/ Universidad Peruana Cayetano Heredia, Lima, Peru"}]

    Find Clinical Drug Pipeline Developments & Deals for Fenbendazole

    Menu

    Fenbendazole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Universidad Peruana Cayetano Heredia

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Universidad Peruana Cayetano Heredia

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenbendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Oxfendazole Development Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oxfendazole in Mild Parenchymal Brain Cysticercosis

                            Details : Oxfendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Neurocysticercosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 22, 2024

                            Lead Product(s) : Fenbendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Oxfendazole Development Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Universidad Peruana Cayetano Heredia

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Universidad Peruana Cayetano Heredia

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenbendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : National Institute of Allergy and Infectious Diseases | Oxfendazole Development Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis

                            Details : Oxfendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fascioliasis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 16, 2024

                            Lead Product(s) : Fenbendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : National Institute of Allergy and Infectious Diseases | Oxfendazole Development Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oxfendazole Development Group

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Oxfendazole Development Group

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenbendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Universidad Peruana Cayetano Heredia, Lima, Peru

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults

                            Details : Oxfendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Trichuriasis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 19, 2018

                            Lead Product(s) : Fenbendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Universidad Peruana Cayetano Heredia, Lima, Peru

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth